enGene Therapeutics Inc. filings document the regulatory record of a clinical-stage biotechnology issuer focused on non-viral genetic medicines. The company’s SEC reports cover Nasdaq-listed common shares and warrants, emerging growth company status, clinical disclosures for detalimogene voraplasmid and the LEGEND trial, and material agreements tied to financing and operating arrangements.
Recent filings include Form 8-K reports on clinical and financial updates, amendments to a loan and security agreement, an at-the-market sales agreement under a shelf registration statement, executive compensation arrangements, and the completed corporate name change from enGene Holdings Inc. Proxy materials cover annual meeting matters, audited financial statements, director elections, auditor appointment, governance proposals, and shareholder voting procedures.
enGene Holdings Inc. filed Amendment No. 1 to its annual report to add the previously omitted Part III disclosures on directors, governance, executive compensation, ownership and auditor matters, and to update certain exhibits.
The amendment does not change prior financial statements and is meant to be read together with the original annual report. It details a nine‑member, majority‑independent, staggered board, outlines the roles of key committees, and describes the company’s code of conduct and insider trading policy. It also provides 2025 compensation data for the CEO, CFO and Chief Medical Officer and summarizes the 2023 Incentive Equity Plan, including stock option practices, severance terms and change‑of‑control treatment for equity awards.
enGene Holdings Inc. (ENGN) received an updated large-holder disclosure as Venrock-affiliated funds and related individuals reported beneficial ownership of 4,771,414 Common Shares, representing 7.1% of the company as of December 31, 2025.
The ownership is spread across Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., and related management entities, with Nimish Shah and Bong Y. Koh as voting members. The percentage is based on 66,984,661 Common Shares outstanding as of December 17, 2025. The group certifies the shares were not acquired to change or influence control of enGene.
Cormorant Asset Management, LP and Bihua Chen have disclosed a significant passive stake in enGene Holdings Inc. common shares. They report beneficial ownership of 4,000,000 common shares, representing 5.97% of the class, held through certain Cormorant funds.
The percentage is calculated using 66,984,661 common shares outstanding as of December 17, 2025, as stated in enGene’s Form 10-K. All 4,000,000 shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive power. The holding is certified as being in the ordinary course of business and not for the purpose of changing or influencing control of enGene.
Kynam Capital Management and related reporting persons disclose a 2.23% beneficial stake in enGene Holdings Inc. common shares on an amended Schedule 13G. They report beneficial ownership of 1,492,898 common shares, with shared voting and dispositive power and no sole voting or dispositive authority.
The filing names Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang as reporting persons and certifies the shares are held in the ordinary course of business, not for the purpose of changing or influencing control of enGene.
enGene Holdings Inc. reported a new equity award to its Chief Scientific Officer, Anthony Tzeyew Cheung. On January 30, 2026, he received a stock option to buy 195,000 common shares at an exercise price of $9.53 per share.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owns 195,000 derivative securities directly, aligning his compensation more closely with the company’s future share performance.
enGene Holdings Inc. reported a new stock option grant to its Chief Legal Officer and Corporate Secretary, Lee G. Giguere. On 01/30/2026, Giguere received a stock option for 195,000 common shares with an exercise price of $9.53, reported as held directly.
The option was granted at no cost and is structured to vest monthly in substantially equal amounts over 48 months, subject to Giguere’s continued service with the company. After this grant, Giguere beneficially owned 195,000 stock options tied to enGene common shares.
enGene Holdings Inc. granted a stock option to Chief Strategy & Ops Officer Alexander Julian Nichols covering 195,000 common shares on January 30, 2026.
The option has an exercise price of $9.53 per share and expires on January 30, 2036. It was granted at no cost to the reporting person and vests in substantially equal monthly installments over 48 months, conditioned on continued service. After this grant, Nichols beneficially owns 195,000 derivative securities directly.
enGene Holdings Inc. reported that Chief Financial Officer D. Ryan Daws received a new stock option grant. On 01/30/2026, he was awarded a Stock Option (Right to Buy) covering 220,000 common shares at an exercise price of $9.53 per share, for no upfront cost.
The option expires on 01/30/2036 and is held directly. It vests monthly in substantially equal amounts over 48 months, conditioned on his continued service with the company, so the right to purchase shares builds gradually over four years rather than all at once.
enGene Holdings Inc. CEO & President Ronald Harold Wilfred Cooper was granted a large stock option award. On 01/30/2026, he received a stock option covering 801,000 common shares at an exercise price of $9.53 per share. The option was reported as held directly.
The option vests monthly in substantially equal amounts over 48 months, conditioned on his continued service. After this grant, he beneficially owned 801,000 derivative securities tied to common shares through this option award.
enGene Holdings Inc. chief technology officer Joan Connolly received a stock option grant for 195,000 common shares on January 30, 2026. The options give her the right to buy these shares at an exercise price of $9.53 per share and expire on January 30, 2036.
The award vests monthly in substantially equal installments over 48 months, contingent on her continued service with the company. This Form 4 reports an incentive-based equity grant, with Connolly directly holding 195,000 derivative securities following the transaction.